Study of Ivosidenib (AK112) with chemo and radiation for advanced colorectal cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a new combination of drugs (Ivosidenib/AK112, CapeOX chemotherapy, and radiation) for people with advanced colorectal cancer that has spread and cannot be removed with surgery. It is for those whose tumors are MSS (microsatellite stable) type and who have not received recent chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You are able to take care of yourself and are up and about most of the day (ECOG 0-1).
- You have colorectal cancer that has spread to other parts of the body and cannot be removed with surgery right now.
- Your tumor is MSS (microsatellite stable) or pMMR (mismatch repair proficient).
- You have not had chemotherapy for this cancer in the past year (or never had it).
- Your heart, liver, kidneys, and blood clotting are working well, as shown by recent tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called AK104 combined with standard chemotherapy and either cetuximab or bevacizumab for people with metastatic colorectal cancer that cannot be surgically removed. It is for those who have had only one prior line of treatment and whose tumors are not MSI-H or have a BRAF mutation.
This trial tests a new immunotherapy drug (AK112) given after a short course of radiation. It is for people with a specific type of mid-low rectal cancer that has not spread and has not been treated before.
This trial tests a combination of three drugs (irinotecan liposomes, cetuximab, and vemurafenib) for people with advanced colorectal cancer that has a specific genetic change (BRAF V600E mutation) and did not respond to first treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests a new drug combination (IBI351, cetuximab, and FOLFIRI) as first treatment or as a second treatment after standard chemotherapy for people with KRAS G12C mutated colorectal cancer that has spread. The goal is to see if it works well and is safe.
This trial is for people with a certain type of advanced colorectal cancer (MSS/pMMR) that has progressed after initial chemotherapy. It tests a new drug called AK112 combined with chemotherapy, compared to the standard treatment with bevacizumab plus chemotherapy. The goal is to see if the new combination works better as a second treatment option.
This trial tests a new drug called AK112 combined with chemotherapy as a first treatment for people with metastatic colorectal cancer. The goal is to see if the combination helps shrink tumors and improve survival better than chemotherapy alone.
Hear when a new CRC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.